Accelerated approval
Accelerated approval
A US FDA pathway for serious conditions and unmet need, using a surrogate or intermediate endpoint reasonably likely to predict clinical benefit.
How to read it
Follow confirmatory studies and associated requirements.
A common pitfall
Accelerated approval differs from priority review and leaves uncertainty requiring further evidence.
Read it in context
Related readings will be added as the collection grows.